Arrowhead Pharmaceuticals (ARWR)
(Real Time Quote from BATS)
$23.71 USD
-0.37 (-1.54%)
Updated Aug 30, 2024 12:16 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ARWR 23.71 -0.37(-1.54%)
Will ARWR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARWR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARWR
Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates
ARWR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ARWR
Stocks with three weeks of deteriorating technicals by Piper Sandler
Arrowhead Pharmaceuticals: A Cautious Hold Amid Promising Obesity Treatments and Competitive Market
Arrowhead Pharmaceuticals’ Breakthrough Obesity Treatments Propel Buy Rating
Piper Sandler Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)
Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK), Arrowhead Pharmaceuticals (ARWR) and Syndax Pharmaceuticals (SNDX)